Erratum: The biology and future prospects of antivirulence therapies (Nature Reviews Microbiology (2008) vol. 6 (17-27) 10.1038/nrmicro1818);The biology and future prospects of antivirulence therapies

Nature Reviews Microbiology

Volumn 6, Issue 1, 2008, Pages 17-27

  Cegelski, Lynette ^a   Marshall, Garland R ^b   Eldridge, Gary R ^c   Hultgren, Scott J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c Sequoia Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; ANTHRAX TOXIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL TOXIN; BOTULINUM ANTISERUM; C 30; CHOLERA TOXIN; CIPROFLOXACIN; DODECYL SULFATE SODIUM; FURANONE DERIVATIVE; METICILLIN; MONOCLONAL ANTIBODY; PALIVIZUMAB; PLACEBO; SHIGA TOXIN; TOBRAMYCIN; UNCLASSIFIED DRUG; VALORTIM; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACILLUS ANTHRACIS; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BACTERIUM PILUS; BIOFILM; BIOLOGICAL WARFARE; BOTULISM; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DRUG DESIGN; DRUG MECHANISM; DRUG TARGETING; ESCHERICHIA COLI; HOST PATHOGEN INTERACTION; HUMAN; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUORUM SENSING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RIBOSWITCH; SHIGELLA DYSENTERIAE; STAPHYLOCOCCUS INFECTION; TYPE III SECRETION SYSTEM; URINARY TRACT INFECTION; VIRUS INFECTION;

BACTERIA (MICROORGANISMS);

EID: 37349002541     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro2244     Document Type: Erratum

References (102)

1. Alekshun, M. N. & Levy S. B. Molecular mechanisms of antibacterial multidrug resistance. Cell 128, 1037-1050(2007).
2. Livermore, D. M. Minimising antibiotic resistance. Lancet Infect. Dis. 5, 450-459 (2005).
3. Palumbi, S. R. Humans as the world's greatest evolutionary force. Science 293, 1786-1790 (2001).
4. Vicente, M. et al. The fallacies of hope: Will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol. Rev. 30, 841-852 (2006).
5. Levy, S. B. & Marshall, B, Antibacterial resistance worldwide: Causes, challenges and responses. Nature Med. 10, S122-S129 (2004).
6. Crowley, P. J. & Martini, L. G. Formulation design: New drugs from old. Drug Discov. Today: Therapeutic Strategies 1, 537-542 (2004).
7. Projan, S. J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6, 427-430 (2003).
8. Fernandes, P. Antibacterial discovery and development - the failure of success? Nature Biotechnol. 24, 1497-1503 (2006).
9. Talbot, G. H. et al. Bad bugs need drugs: An update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin. Infect. Dis. 42, 657-668 (2006).
10. Blount, K. F., Wang. J. X., Lim, J., Sudarsan, N. & Breaker, R. R. Antibacterial lysine analogs that target lysine riboswitches. Nature Chem. Biol. 3, 44-49 (2007).
11. Wright, G. D. The antibiotic resistome: The nexus of chemical and genetic diversity. Nature Rev. Microbiol. 5, 175-186 (2007).
12. Mwangi, M. M. et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl Acad. Sci. USA 104, 9451-9456 (2007).
13. Finlay, B. B. & Falkow, S. Common themes in microbial pathogenicity revisited. Microbiol. Mol. Biol. Rev. 61, 136-169 (1997).
14. Lee, Y. M., Almqvist, F. & Hultgren, S. J. Targeting virulence for antimicrobial chemotherapy. Curr. Opin. Pharmacol. 3, 513-519 (2003).
15. Marra, A. Can virulence factors be viable antibacterial targets? Expert Rev. Anti. Infect. Ther. 2, 61-72 (2004).
16. Savage, D. C. Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. 31, 107-133 (1977).
17. Backhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718-15723 (2004).
18. Miller, J. F., Mekalanos, J. J. & Falkow, S. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science 243, 916-922 (1989).
19. Virgin. H. W. In vivo veritas: Pathogenesis of infection as it actually happens. Nature Immunol. 8, 1143-1147 (2007).
20. Moxon, E. R., Rainey, P. B., Nowak, M. A. & Lenski, R. E. Adaptive evolution of highly mutable loci in pathogenic bacteria. Curr. Biol. 4, 24-33 (1994).
21. Monack, D. M., Mueller, A. & Falkow, S. Persistent bacterial infections: the interface of the pathogen and the host immune system. Nature Rev. Microbiol. 2, 747-765 (2004).
22. Kaufmann, S. H. E. The contribution of immunology to the rational design of novel antibacterial vaccines. Nature Rev. Microbiol. 5, 491-504 (2007).
23. Kokai-Kun, J. F. & Mond, J. J. Antibody therapy for treatment or prevention of infectious diseases. Drug Discov. Today: Therapeutic Strategies 1, 475-481 (2004).
24. Pirofski, L. A. & Casadevall, A. Immunomodulators as an antimicrobial tool. Curr. Opin. Microbiol. 9, 489-495 (2006).
25. Hung, D. L. & Hultgren, S. J. Pilus biogenesis via the chaperone/usher pathway: An integration of structure and function. J. Struct. Biol. 124, 201-220 (1998).
26. Telford, J. L., Barocchi, M. le A., Margarit, I., Rappuoli, R. & Grandi, G. Pili in Gram-positive pathogens. Nature Rev. Microbiol. 4 509-519 (2006).
27. Barocchi, M. A. et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc. Natl Acad. Sci. USA 103 2857-2862 (2006).
28. Mulvey. M. A. Adhesion and entry of uropathogenic Eschenchia coli. Cell. Microbiol. 4, 257-271 (2002).
29. Garofalo, C. K. et al. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect. Immun. 75, 52-60 (2007).
30. Martinez, J. J., Mulvey, M. A., Schilling, J. D., Pinkner, J. S. & Hultgren, S. J. Type I pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J. 19, 2803-2812 (2000).
31. Sauer, F. G., Mulvey, M. A., Schilling, J. D.. Martinez, J. J. & Hultgren, S. J. Bacterial pili: Molecular mechanisms of pathogenesis. Curr. Opin. Microbiol 3, 65-72 (2000).
32. Anderson. G. G. et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Sciences 301, 105-107 (2003).
33. Justice, S. S. et al. Differentiation and developmental pathways of uropathogenic Escherichio coli in urinary tract pathogenesis. Proc. Natl Acad. Sci. USA 101, 1333-1338 (2004).
34. Rosen Da, H. T, Stamm W. E., Humphrey, P. A. & Hultgren, S. J. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. (in the press).
35. Mulvey, M. A. et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282, 1494-1497 (1998).
36. Mysorekar, I. U. & Hultgren, S. J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl Acad. Sci. USA 103, 14170-14175 (2006).
37. Wright, K. J., Seed, P. C. & Hultgren. S. J. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol. 9, 2230-2241 (2007).
38. Kihlberg, J. & Magnusson, G. Use of carbohydrates and peptides in studies of adhesion of pathogenic bacteria and in efforts to generate carbohydrate-specific T cells. Pure Appl. Chem. 68. 2119-2128 (1996).
39. Firon, N., Ashkenazi, S., Mirelman, D.. Ofek, I. & Sharon, N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. Infect. Immun. 55, 472-476 (1987).
40. Bouckaert, J. et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol. Microbiol. 55, 441-455 (2005).
41. Sauer, F. G., Remaut, H., Hultgren, S. J. & Waksman, G. Fiber assembly by the chaperone-usher pathway. Biochim. Biophys. Acta 1694, 259-267 (2004).
42. Chen, S. L. et al. Identification of genes subject to positive selection in uropathogenic strains of Escherichia coli: A comparative genomics approach. Proc. Natl Acad. Sci. USA 103 5977-5982 (2006).
43. Svensson, A. et al. Design and evaluation of pilicides: Potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2, 915-918 (2001).
44. Larsson, A. et al. Multivariate design, synthesis, and biological evaluation of peptide inhibitors of FimC/FimH protein-protein interactions in uropathogenic Escherichia coli. J. Med. Chem. 48, 935-945 (2005).
45. Pinkner, J. S. et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl Acad. Sci. USA 103, 17897-17902 (2006).
46. Report No. 04-5512, 153-183 (US Government Printing Office, Washington DC, 2004).
47. Report No. 04-5512, 187-209 (US Government Printing Office, Washington DC, 2004).
48. Ronald, A. R. et al. Urinary tract infection in adults: Research priorities and strategies. Int. J. Antimicrob. Agents 17, 343-348 (2001).
49. Acharya, V. N. Urinary tract infection - a dangerous and unrecognised forerunner of systemic sepsis. J. Postgrad. Med. 38, 52-54 (1992).
50. Schmitt, C. K., Meysick, K. C. & O'Brien, A D. Bacterial toxins: Friends or foes? Emerg. Infect. Dis. 5 224-234 (1999).
51. Spangler, B, D. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56, 622-647 (1992).
52. Hung, D. T, Shakhnovich, E. A., Pierson, E. & Mekalanos, J. J. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310, 670-674 (2005).
53. Keller, M. A. & Stiehm, E. R. Passive immunity in prevention and treatment of infectious diseases. Clin. Microbiol. Rev. 13, 602-614 (2000).
54. Annon, S. S., Schechter, R., Maslanka, S. E., Jewell, N. P. & Hatheway, C. L Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 354, 462-471 (2006).
55. Young. J. A. & Collier, R. J. Anthrax toxin: Receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76, 243-265 (2007).
56. Saenz, J. B., Doggett, T. A. & Haslam, D. B. Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect. Immun. 75, 4552-4561 (2007).
57. Zhao, L & Haslam, D. B. A quantitative and highly sensitive luciferase-based assay for bacterial toxins that inhibit protein synthesis, J. Med. Microbiol. 54, 1023-1030 (2005).
58. Tonello, F., Seveso, M., Marin, O., Mock, M. & Montecucco, C. Screening inhibitors of anthrax lethal factor. Nature 418, 386 (2002).
59. Panchal, R. G. et al. Identification of small molecule inhibitors of anthrax lethal factor. Nature Struct. Mol. Biol. 11, 67-72 (2004).
60. Turk, B. E. et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nature Struct. Mol. Biol. 11, 60-66 (2004).
61. Russell, P. K. Project BioShield: What it is, why it is needed, and its accomplishments so far. Clin. Infect. Dis. 45, S68-S72 (2007).
62. US Securities and Exchange Commission (SEC). Pharmathene, Inc. Form 10-Q, Quarter Ended September 30, Commission File Number 001-32587. SEC web site [online], http://www.sec.gov/Archives/edgar/data/ 1326190/000110465907083136/a07-29212_110a.htm#Item2_103948 (2007).
63. Food and Drug Administration Center for Drug Evaluation and Research. Summary Minutes of the Anti-Infective Drugs Advisory Committee on April 12, 2007 [online], http://www.fda.gov/ohrms/dockets/AC/07/ minutes/2007-4286m1.pdf (2007).
64. Gyles, C. L. Shiga toxin-producing Escherichia coli: An overview. J. Anim. Sci. 85, E45-E62 (2007).
65. Sandkvist, M. et al. General secretion pathway (eps) genes required for toxin secretion and outer membrane biogenesis in Vibrio cholerae. J. Bacteriol. 179, 6994-7003 (1997).
66. Cornelis, G. R. The type III secretion injectisome. Nature Rev. Microbiol. 4, 811-825 (2006).
67. Cornelis, G. R. & Wolf-Watz, H. The Yersinia Yop virulon: A bacterial system for subverting eukaryotic cells. Mol. Microbiol. 23, 861-867 (1997).
68. Cornelis. G. R. Yersinia type III secretion: Send in the effectors. J. Cell. Biol. 158, 401-404 (2002).
69. Cornelis, G. R. & Van Gijsegem, F. Assembly and function of type III secretory systems. Annu. Rev. Microbiol. 54, 735-774 (2000).
70. Rosqvist, R., Hakansson, S., Forsberg, A. & Wolf-Watz, H. Functional conservation of the secretion and translocation machinery for virulence proteins of yersiniae, salmonellae and shigellae. EMBO J. 14 4187-4195 (1995).
71. Kauppi, A. M., Nordfelth, R., Uvell, H., Wolf-Watz, H. & Elofsson, M. Targeting bacterial virulence: Inhibitors of type III secretion in Yersinia. Chem. Biol. 10, 241-249 (2003).
72. Nordfelth, R., Kauppi, A. M., Norberg, H. A., Wolf-Watz, H. & Elofsson, M. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73, 3104-3114 (2005).
73. Wolf, K. et al. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol. Microbiol. 61, 1543-1555 (2006).
74. Muschiol, S. et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl Acad. Sci. USA 103, 14566-14571 (2006).
75. Bailey, L. et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 581, 587-595 (2007).
76. Saye, D. E. Recurring and antimicrobial-resistant infections: considering the potential role of biofilms in clinical practice. Ostomy Wound Manage. 53, 46-62 (2007).
77. Hall-Stoodley L et al. Direct detection of bacterial biofllms on the middle-ear mucosa of children with chronic otitis media. JAMA 296, 202-211 (2006).
78. Carron, M. A., Tran, V. R., Sugawa, C. & Coticchia, J. M. Identification of Helicobacter pylori biofilms in human gastric mucosa. J. Gastrointest Surg. 10, 712-717 (2006).
79. Lam, J., Chan, R., Lam, K & Costerton, J. W. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect. Immun. 28, 546-556 (1980).
80. Singh. P. K. et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407 762-764 (2000).
81. Benghezal, M. et al. Inhibitors of bacterial virulence identified in a surrogate host model. Cell. Microbiol. 9, 1336-1342 (2007).
82. Keller, L & Surette, M. G. Communication in bacteria: An ecological and evolutionary perspective. Nature Rev. Microbiol. 4, 249-258 (2006).
83. Bassler. B. L. & Losick, R. Bacterially speaking. Cell 125, 237-246 (2006).
84. Kjelleberg, S. et al. Do marine natural products interfere with prokaryotic AHL regulatory systems? Aquat. Microb. Ecol. 13, 85-93 (1997).
85. Manefield, M. et al. Evidence that halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone (AHL)-mediated gene expression by displacing the AHL signal from its receptor protein [in process citation]. Microbiology 145, 283-291 (1999).
86. Higgins, D. A. et al. The major Vibrio cholerae autoinducer and its role in virulence factor production. Nature 14 Nov 2007 (doi:10.1038/nature06284).
87. Hentzer, M. et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22, 3803-3815 (2003).
88. Bjarnsholt, T. & Givskov, M. Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Phil. Trans. R. Soc. Lond. B 362, 1213-1222 (2007).
89. Geske, G. D., O'Neill, J.C. & Blackwell, H. E. N phenylacetanoyl-L-homoserine lactones can strongly antagonize or superagonize quorum sensing in Vibrio fischeri. ACS Chem. Biol. 2, 15-319 (2007).
90. Miller, M. B., Skorupski, K., Lenz, D. H., Taylor, R. K. & Bassler, B. L. Parallel quorum sensing systems converge to regulate virulence in Vibrio cholerae. Cell 110, 303-314 (2002).
91. Wadhams, G. H. & Armitage, J. P. Making sense of it all: Bacterial chemotaxis. Nature Rev. Mol. Cell Biol. 6, 1024-1037 (2004).
92. Galperin, M. Y. Structural classification of bacterial response regulators: Diversity of output domains and domain combinations. J. Bacteriol. 188, 4169-4182 (2006).
93. Ulrich, L. E. & Zhulin, I. B. MiST: A microbial signal transduction database. Nucleic Acids Res. 35, D386-D390 (2007).
94. Mascher, T., Helmann, J. D. & Unden, G. Stimulus perception in bacterial signal-transducing histidine kinases. Microbiol. Mol. Biol. Rev. 70, 910-938 (2006).
95. Barrett, J. F. & Hoch, J. A. Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob. Agents Chemother. 42, 1529-1536 (1998).
96. Mayville, P. et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc. Natl Acad. Sci. USA 96, 1218-1223 (1999).
97. Otto, M. Quorum-sensing control in Staphylococci - a target fbr antimicrobial drug therapy? FEMS Microbiol. Lett. 241, 135-141 (2004).
98. Arthur, M., Molinas, C. & Courvalin, P. The VanS - VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147. J. Bacteriol. 174, 2582-2591 (1992).
99. Evers, S. & Courvalin, P. Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR (B) two-component regulatory system in Enterococcus faecalis V583. J. Bacteriol. 178, 1302-1309 (1996).
100. Sintchenko, V., Iredell, J. R. & Gilbert, G. L. Pathogen profiling for disease management and surveillance. Nature Rev. Microbiol. 5 464-470 (2007).
101. Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29-40 (2007).
102. Jones, C. H. et al. FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae. Proc. Natl Acad. Sci. USA 92, 2081-2085 (1995).